



CIN: L24230GJ1972PLC002126
 Website: www.torrentpharma.com
 Email: investorservices@torrentpharma.com

TORRENT PHARMACEUTICALS LIMITED

Registered Office:
 Torrent House, Off Ashram Road,
 Ahmedabad - 380 009, Gujarat, India.
 Ph. : + 91 79 26599000
 Fax : + 91 79 26582100

**Extract of Consolidated Financial Results
 for the Quarter and Year ended 31-Mar-2023**

[₹ in crores except per share data]

Particulars	Quarter Ended 31-Mar-2023	Year Ended 31-Mar-2023	Quarter Ended 31-Mar-2022
	Audited (Refer Note 2)	Audited	Audited (Refer Note 2)
Total Income from operations (net)	2491	9620	2131
Net Profit / (Loss) for the period before tax and exceptional items	433	1847	398
Net Profit / (Loss) for the period before tax and after exceptional items	433	1847	(87)
Net Profit / (Loss) for the period after tax and exceptional items	287	1245	(118)
Total Comprehensive Income (after tax)	330	1108	(107)
Equity Share Capital	169.23	169.23	84.62
Other Equity excluding Revaluation Reserve		6029	
Earnings per share (of ₹ 5/- each) (Refer Note 3)			
Basic	8.48	36.79	(3.49)
Diluted	8.48	36.79	(3.49)

* Other Equity excluding Revaluation Reserve as on 31-Mar-2022 was ₹ 5868 crores.

Notes :

1 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :

[₹ in crores]

Particulars	Quarter Ended 31-Mar-2023	Year Ended 31-Mar-2023	Quarter Ended 31-Mar-2022
Net income from operations	1920	7695	1662
Profit before tax	328	1577	345
Profit after tax	219	1052	221
Total Comprehensive Income (after tax)	240	974	219

- 2 The figures for the quarter ended 31-Mar-2023 and 31-Mar-2022 is the balancing figures between audited figures in respect of the full financial year and for the period upto the end of the third quarter ended 31-Dec-2022 (as restated to give effect of amalgamation as per Note 4) and 31-Dec-2021, respectively, which were subject to limited review.
- 3 Pursuant to approval given by its shareholders, the company has during the year ended 31-Mar-2023, issued 16,92,22,720 equity shares of ₹ 5/- each as fully paid-up bonus equity shares in the ratio of 1 (one) equity share for every 1 (one) existing equity share. Accordingly, the earnings per share has been adjusted for previous periods and presented in accordance with Ind AS 33, Earnings Per Share.
- 4 On 14-Oct-2022, the Company acquired 100% shares of Curatio Healthcare (I) Private Limited ('Curatio'), including its two subsidiaries. The Board of Directors of the Company, at its meeting held on 21-Dec-2022, had approved the Scheme of Arrangement in the nature of Amalgamation of Curatio with the Company. The scheme was approved by the National Company Law Tribunal ('NCLT'), Ahmedabad Bench on 17-May-2023 with the appointed date of 14-Oct-2022. The financial statements for the quarter and year ended 31-Mar-2023 are after giving effect to the amalgamation in books of accounts. Hence, the quarter ended figures, to that extent are not comparable.
- 5 The Board of Directors in their meeting held on 30-May-2023, recommended a final equity dividend of ₹ 8/- per equity share.
- 6 The above is an extract of the detailed format of Financial Results for the quarter and year ended 31-Mar-2023 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on www.nseindia.com, www.bseindia.com and on the Company's website www.torrentpharma.com.

Place : Mumbai, Maharashtra
 Date : 30-May-2023



CIN: L24230GJ1972PLC002126
Website: www.torrentpharma.com
Email: investorservices@torrentpharma.com

TORRENT PHARMACEUTICALS LIMITED

Registered Office:
Torrent House, Off Ashram Road,
Ahmedabad - 380 009, Gujarat, India.
Ph. : + 91 79 26599000
Fax : + 91 79 26582100

**Extract of Consolidated Financial Results
for the Quarter and Year ended 31-Mar-2023**

[₹ in crores except per share data]

Particulars	Quarter Ended 31-Mar-2023	Year Ended 31-Mar-2023	Quarter Ended 31-Mar-2022
	Audited (Refer Note 2)	Audited	Audited (Refer Note 2)
Total Income from operations (net)	2491	9620	2131
Net Profit / (Loss) for the period before tax and exceptional items	433	1847	398
Net Profit / (Loss) for the period before tax and after exceptional items	433	1847	(87)
Net Profit / (Loss) for the period after tax and exceptional items	287	1245	(118)
Total Comprehensive Income (after tax)	330	1108	(107)
Equity Share Capital	169.23	169.23	84.62
Other Equity excluding Revaluation Reserve*		6029	
Earnings per share (of ₹ 5/- each) (Refer Note 3)			
Basic	8.48	36.79	(3.49)
Diluted	8.48	36.79	(3.49)

* Other Equity excluding Revaluation Reserve as on 31-Mar-2022 was ₹ 5868 crores.

Notes :

1 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :
[₹ in crores]

Particulars	Quarter Ended 31-Mar-2023	Year Ended 31-Mar-2023	Quarter Ended 31-Mar-2022
Net income from operations	1920	7695	1662
Profit before tax	328	1577	345
Profit after tax	219	1052	221
Total Comprehensive Income (after tax)	240	974	219

- The figures for the quarter ended 31-Mar-2023 and 31-Mar-2022 is the balancing figures between audited figures in respect of the full financial year and for the period upto the end of the third quarter ended 31-Dec-2022 (as restated to give effect of amalgamation as per Note 4) and 31-Dec-2021, respectively, which were subject to limited review.
- Pursuant to approval given by its shareholders, the company has during the year ended 31-Mar-2023, issued 16,92,22,720 equity shares of ₹ 5/- each as fully paid-up bonus equity shares in the ratio of 1 (one) equity share for every 1 (one) existing equity share. Accordingly, the earnings per share has been adjusted for previous periods and presented in accordance with Ind AS 33, Earnings Per Share.
- On 14-Oct-2022, the Company acquired 100% shares of Curatio Healthcare (I) Private Limited ('Curatio'), including its two subsidiaries. The Board of Directors of the Company, at its meeting held on 21-Dec-2022, had approved the Scheme of Arrangement in the nature of Amalgamation of Curatio with the Company. The scheme was approved by the National Company Law Tribunal ('NCLT'), Ahmedabad Bench on 17-May-2023 with the appointed date of 14-Oct-2022. The financial statements for the quarter and year ended 31-Mar-2023 are after giving effect to the amalgamation in books of accounts. Hence, the quarter ended figures, to that extent are not comparable.
- The Board of Directors in their meeting held on 30-May-2023, recommended a final equity dividend of ₹ 8/- per equity share.
- The above is an extract of the detailed format of Financial Results for the quarter and year ended 31-Mar-2023 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on www.nseindia.com, www.bseindia.com and on the Company's website www.torrentpharma.com.

Place : Mumbai, Maharashtra
Date : 30-May-2023